Director Eric Shuey executed a transaction involving LifeStance Health Group, Inc. (NASDAQ:LFST) common stock on May 12, 2026. Specifically, Mr. Shuey sold a total of 243,362 shares of the company's common stock.
The sale was executed at a price point of $8.02 per share, generating proceeds totaling approximately $1,951,763. It is worth noting that this transaction occurred while the stock had experienced an 8.5% decline over the preceding week, although its performance remained up 41% compared to levels one year prior.
The shares sold were held indirectly through the Eric Shuey Gift Trust. Following the completion of this disposition, the trust retained ownership of 867,562 shares of LifeStance Health common stock. Mr. Shuey explicitly disclaimed beneficial ownership of these securities, retaining only a pecuniary interest to the extent permitted by law.
In addition to the stake held via the trust, Mr. Shuey maintains a direct holding of 93,982 shares of LifeStance Health Group, Inc. common stock.
Beyond the reported insider activity, recent corporate developments provide context for LFST's valuation and capital structure. Financial reporting revealed that LifeStance Health Group posted impressive financial results for the first quarter of 2026. The company achieved an earnings per share (EPS) of $0.04, a figure that notably surpassed the anticipated forecast of $0.01. Furthermore, reported revenue reached $403.48 million, exceeding market expectations of $387.43 million.
In terms of capital transactions, LifeStance Health Group also completed a secondary offering involving 35 million shares. These shares were priced at $8.15 each and were sold by existing stockholders. Critically, the company did not receive any proceeds from this specific offering; all generated funds went directly to the selling stockholders.
Complementing the sale, LifeStance Health also announced intentions to repurchase 6 million shares from the selling stockholders at the identical price paid by the underwriter. J.P. Morgan Securities LLC served as the underwriter for this recent transaction. These events were preceded by a related SEC filing concerning the offering, which was filed under a shelf registration statement. The entire secondary offering concluded earlier in the current week, representing a notable financial activity for the company’s stockholders.
Risks
- The sale of a significant block of stock by an internal director (Eric Shuey) could signal potential loss of confidence or liquidity needs within the company's leadership.
- The secondary offering and subsequent share repurchase plan, while raising capital for selling stockholders, do not provide any direct proceeds to LifeStance Health Group itself.
More from Insider Trading
Risks
- The sale of a significant block of stock by an internal director (Eric Shuey) could signal potential loss of confidence or liquidity needs within the company's leadership.
- The secondary offering and subsequent share repurchase plan, while raising capital for selling stockholders, do not provide any direct proceeds to LifeStance Health Group itself.